IDEAS home Printed from https://ideas.repec.org/a/oup/scippl/v24y1997i1p53-62.html
   My bibliography  Save this article

Biological medicines in the age of biotech: Public policy issues

Author

Listed:
  • Norma Morris

Abstract

The class of medicines known as ‘biologicals’ offer unique benefits and have been major life savers but they present particular problems for control of their purity and potency. In the past decade advances in molecular biology and methods of manufacture using biotechnology have led to an explosion of products and opened up new areas for treatment of disease. Is the current regulatory framework adequate for the protection of the public health? How will it be affected by political and economic trends which are causing government to question all public-sector activities, including control of biologicals? The issues include the impact of scientific and technical developments on regulatory workload, unresolved scientific questions of safety, impact of reduced public-sector funding, public input, social and ethical questions raised by new technology, and UK policy with regard to the increasing use and manufacture of biologicals in the developing world. Copyright , Beech Tree Publishing.

Suggested Citation

  • Norma Morris, 1997. "Biological medicines in the age of biotech: Public policy issues," Science and Public Policy, Oxford University Press, vol. 24(1), pages 53-62, February.
    • Handle: RePEc:oup:scippl:v:24:y:1997:i:1:p:53-62
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1093/spp/24.1.53
    Download Restriction: Access to full text is restricted to subscribers.
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Morris, Norma, 2000. "Vial bodies: conflicting interests in the move to new institutional relationships in biological medicines research and regulation," Research Policy, Elsevier, vol. 29(2), pages 149-167, February.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:oup:scippl:v:24:y:1997:i:1:p:53-62. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Oxford University Press (email available below). General contact details of provider: https://academic.oup.com/spp .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.